These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
205 related items for PubMed ID: 24462901
1. Tumor priming enhances siRNA delivery and transfection in intraperitoneal tumors. Wang J, Lu Z, Yeung BZ, Wientjes MG, Cole DJ, Au JL. J Control Release; 2014 Mar 28; 178():79-85. PubMed ID: 24462901 [Abstract] [Full Text] [Related]
2. Paclitaxel tumor priming promotes delivery and transfection of intravenous lipid-siRNA in pancreatic tumors. Wang J, Lu Z, Wang J, Cui M, Yeung BZ, Cole DJ, Wientjes MG, Au JL. J Control Release; 2015 Oct 28; 216():103-10. PubMed ID: 26272765 [Abstract] [Full Text] [Related]
4. Multifunctional Polymeric Micelles Co-loaded with Anti-Survivin siRNA and Paclitaxel Overcome Drug Resistance in an Animal Model of Ovarian Cancer. Salzano G, Navarro G, Trivedi MS, De Rosa G, Torchilin VP. Mol Cancer Ther; 2015 Apr 28; 14(4):1075-84. PubMed ID: 25657335 [Abstract] [Full Text] [Related]
8. Bioinspired tumor-homing nanoplatform for co-delivery of paclitaxel and siRNA-E7 to HPV-related cervical malignancies for synergistic therapy. Xu C, Liu W, Hu Y, Li W, Di W. Theranostics; 2020 Apr 28; 10(7):3325-3339. PubMed ID: 32194871 [Abstract] [Full Text] [Related]
9. Versatility of Particulate Carriers: Development of Pharmacodynamically Optimized Drug-Loaded Microparticles for Treatment of Peritoneal Cancer. Au JL, Lu Z, Wientjes MG. AAPS J; 2015 Sep 28; 17(5):1065-79. PubMed ID: 26089090 [Abstract] [Full Text] [Related]
10. Growth inhibition and chemo-radiosensitization of head and neck squamous cell carcinoma (HNSCC) by survivin-siRNA lentivirus. Khan Z, Khan AA, Prasad GB, Khan N, Tiwari RP, Bisen PS. Radiother Oncol; 2016 Feb 28; 118(2):359-68. PubMed ID: 26747757 [Abstract] [Full Text] [Related]
11. The antitumor effect of a thermosensitive polymeric hydrogel containing paclitaxel in a peritoneal carcinomatosis model. Yu J, Lee HJ, Hur K, Kwak MK, Han TS, Kim WH, Song SC, Yanagihara K, Yang HK. Invest New Drugs; 2012 Feb 28; 30(1):1-7. PubMed ID: 20669041 [Abstract] [Full Text] [Related]
12. Tumor-penetrating microparticles for intraperitoneal therapy of ovarian cancer. Lu Z, Tsai M, Lu D, Wang J, Wientjes MG, Au JL. J Pharmacol Exp Ther; 2008 Dec 28; 327(3):673-82. PubMed ID: 18780831 [Abstract] [Full Text] [Related]
13. Biocompatible AIEgen/p-glycoprotein siRNA@reduction-sensitive paclitaxel polymeric prodrug nanoparticles for overcoming chemotherapy resistance in ovarian cancer. Wu J, Wang Q, Dong X, Xu M, Yang J, Yi X, Chen B, Dong X, Wang Y, Lou X, Xia F, Wang S, Dai J. Theranostics; 2021 Dec 28; 11(8):3710-3724. PubMed ID: 33664857 [Abstract] [Full Text] [Related]